Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis

Jin Suk Kim, Kwang Hyub Han, Do Yun Lee, Jin Sil Seong, Young Hoon Youn, Jae Youn Cheong, Sang Hoon Ahn, Chae Yoon Chon, Young Myoung Moon

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND/AIMS: Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis. This study was undertaken to evaluate the therapeutic effects of concurrent chemo-radiation therapy in advanced hepatocellular carcinoma with portal vein thrombosis. METHODS: A total of 54 patients with advanced hepatocellular carcinoma (TNM stage IVa) were enrolled. Nineteen patients were treated with external beam radiotherapy (4,500 cGy/ 5 weeks) and intrahepatic arterial 5-FU infusion (500 mg on 1-5 day and 30-35 day, respectively) via implanted chemoport. The others were treated with intrahepatic arterial cisplatin infusion (80 mg/m(2)). RESULTS: In patients treated with concurrent chemo-radiation therapy, response rates at 2nd and 6th months were 42.1% and 26.3%, respectively. In patients treated with intrahepatic arterial cisplatin therapy, response rates at 2nd and 6th months were 2.9% and 0%, respectively. The median survival time was 11.6 months in concurrent chemo-radiation therapy and 4.8 months in intrahepatic arterial cisplatin infusion therapy. Concurrent chemo-radiation therapy produced better response rates and longer survival time than those of intrahepatic arterial cisplatin infusion therapy (p<0.05). CONCLUSIONS: Concurrent chemo-radiation therapy achieved favorable results in advanced hepatocellular carcinoma with portal vein thrombosis and can be considered as a treatment option for the management of advanced hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)71-79
Number of pages9
JournalTaehan Kan Hakhoe chi = The Korean journal of hepatology
Volume8
Issue number1
Publication statusPublished - 2002 Mar

Fingerprint

Portal Vein
Hepatocellular Carcinoma
Thrombosis
Radiotherapy
Cisplatin
Therapeutic Uses
Therapeutics
Fluorouracil
Survival Rate
Survival

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kim, Jin Suk ; Han, Kwang Hyub ; Lee, Do Yun ; Seong, Jin Sil ; Youn, Young Hoon ; Cheong, Jae Youn ; Ahn, Sang Hoon ; Chon, Chae Yoon ; Moon, Young Myoung. / Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis. In: Taehan Kan Hakhoe chi = The Korean journal of hepatology. 2002 ; Vol. 8, No. 1. pp. 71-79.
@article{f59720d055624e26be83c4ac071e1da7,
title = "Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis",
abstract = "BACKGROUND/AIMS: Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis. This study was undertaken to evaluate the therapeutic effects of concurrent chemo-radiation therapy in advanced hepatocellular carcinoma with portal vein thrombosis. METHODS: A total of 54 patients with advanced hepatocellular carcinoma (TNM stage IVa) were enrolled. Nineteen patients were treated with external beam radiotherapy (4,500 cGy/ 5 weeks) and intrahepatic arterial 5-FU infusion (500 mg on 1-5 day and 30-35 day, respectively) via implanted chemoport. The others were treated with intrahepatic arterial cisplatin infusion (80 mg/m(2)). RESULTS: In patients treated with concurrent chemo-radiation therapy, response rates at 2nd and 6th months were 42.1{\%} and 26.3{\%}, respectively. In patients treated with intrahepatic arterial cisplatin therapy, response rates at 2nd and 6th months were 2.9{\%} and 0{\%}, respectively. The median survival time was 11.6 months in concurrent chemo-radiation therapy and 4.8 months in intrahepatic arterial cisplatin infusion therapy. Concurrent chemo-radiation therapy produced better response rates and longer survival time than those of intrahepatic arterial cisplatin infusion therapy (p<0.05). CONCLUSIONS: Concurrent chemo-radiation therapy achieved favorable results in advanced hepatocellular carcinoma with portal vein thrombosis and can be considered as a treatment option for the management of advanced hepatocellular carcinoma.",
author = "Kim, {Jin Suk} and Han, {Kwang Hyub} and Lee, {Do Yun} and Seong, {Jin Sil} and Youn, {Young Hoon} and Cheong, {Jae Youn} and Ahn, {Sang Hoon} and Chon, {Chae Yoon} and Moon, {Young Myoung}",
year = "2002",
month = "3",
language = "English",
volume = "8",
pages = "71--79",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "1",

}

Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis. / Kim, Jin Suk; Han, Kwang Hyub; Lee, Do Yun; Seong, Jin Sil; Youn, Young Hoon; Cheong, Jae Youn; Ahn, Sang Hoon; Chon, Chae Yoon; Moon, Young Myoung.

In: Taehan Kan Hakhoe chi = The Korean journal of hepatology, Vol. 8, No. 1, 03.2002, p. 71-79.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis

AU - Kim, Jin Suk

AU - Han, Kwang Hyub

AU - Lee, Do Yun

AU - Seong, Jin Sil

AU - Youn, Young Hoon

AU - Cheong, Jae Youn

AU - Ahn, Sang Hoon

AU - Chon, Chae Yoon

AU - Moon, Young Myoung

PY - 2002/3

Y1 - 2002/3

N2 - BACKGROUND/AIMS: Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis. This study was undertaken to evaluate the therapeutic effects of concurrent chemo-radiation therapy in advanced hepatocellular carcinoma with portal vein thrombosis. METHODS: A total of 54 patients with advanced hepatocellular carcinoma (TNM stage IVa) were enrolled. Nineteen patients were treated with external beam radiotherapy (4,500 cGy/ 5 weeks) and intrahepatic arterial 5-FU infusion (500 mg on 1-5 day and 30-35 day, respectively) via implanted chemoport. The others were treated with intrahepatic arterial cisplatin infusion (80 mg/m(2)). RESULTS: In patients treated with concurrent chemo-radiation therapy, response rates at 2nd and 6th months were 42.1% and 26.3%, respectively. In patients treated with intrahepatic arterial cisplatin therapy, response rates at 2nd and 6th months were 2.9% and 0%, respectively. The median survival time was 11.6 months in concurrent chemo-radiation therapy and 4.8 months in intrahepatic arterial cisplatin infusion therapy. Concurrent chemo-radiation therapy produced better response rates and longer survival time than those of intrahepatic arterial cisplatin infusion therapy (p<0.05). CONCLUSIONS: Concurrent chemo-radiation therapy achieved favorable results in advanced hepatocellular carcinoma with portal vein thrombosis and can be considered as a treatment option for the management of advanced hepatocellular carcinoma.

AB - BACKGROUND/AIMS: Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis. This study was undertaken to evaluate the therapeutic effects of concurrent chemo-radiation therapy in advanced hepatocellular carcinoma with portal vein thrombosis. METHODS: A total of 54 patients with advanced hepatocellular carcinoma (TNM stage IVa) were enrolled. Nineteen patients were treated with external beam radiotherapy (4,500 cGy/ 5 weeks) and intrahepatic arterial 5-FU infusion (500 mg on 1-5 day and 30-35 day, respectively) via implanted chemoport. The others were treated with intrahepatic arterial cisplatin infusion (80 mg/m(2)). RESULTS: In patients treated with concurrent chemo-radiation therapy, response rates at 2nd and 6th months were 42.1% and 26.3%, respectively. In patients treated with intrahepatic arterial cisplatin therapy, response rates at 2nd and 6th months were 2.9% and 0%, respectively. The median survival time was 11.6 months in concurrent chemo-radiation therapy and 4.8 months in intrahepatic arterial cisplatin infusion therapy. Concurrent chemo-radiation therapy produced better response rates and longer survival time than those of intrahepatic arterial cisplatin infusion therapy (p<0.05). CONCLUSIONS: Concurrent chemo-radiation therapy achieved favorable results in advanced hepatocellular carcinoma with portal vein thrombosis and can be considered as a treatment option for the management of advanced hepatocellular carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0036517955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036517955&partnerID=8YFLogxK

M3 - Article

C2 - 12499819

AN - SCOPUS:0036517955

VL - 8

SP - 71

EP - 79

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 1

ER -